A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer
Interventions: DRUG: non-pegylated liposomal doxorubicin|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Ferric carboxymaltose
Sponsor: German Breast Group
Collaborators: Amgen|Roche Pharma AG|Teva Pharmaceuticals USA|Vifor Pharma